Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Source: onclive.com
T Cell Engager News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from T Cell Engager. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In T Cell Engager Today - Breaking & Trending Today
Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
Source: onclive.com
Current Treatment Options in Second-line FL
Experts on follicular lymphoma discuss second-line treatment options available for patients.
Source: onclive.com
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02
BEIJING & SHANGHAI — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and CtM Biotech (Shanghai) Co., Ltd (“CtM Bio”) today jointly…
Source: financialpost.com
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral ... Seite 1
Source: wallstreet-online.de